ERG and prostate cancer: Lanbo Xiao et al. used the degradation agent AU-15,330 to target and reduce the expression of BRG1 in prostate cancer cell lines, leading to the detachment of the transcription factor ERG from chromatin and the inactivation of downstream oncogenes, thereby inhibiting prostate cancer growth [10].